KRYS

Krystal BiotechC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-22

View Chart

Peers tracked

U.S. public peers

Grade Position

In line

vs peer average

KRYS vs peer average

60/100

KRYS vs. peer average (C vs. D)

Grade spread

C 4 · D 3 · F 1

Graded peers loaded

Coverage

8 graded

89% of tracked

Peer overview

CYTK is the first available peer comparator.

Cytokinetics is a more development-heavy biotech peer by market cap, but it lacks KRYS's approved gene-therapy commercial base, so read-through is mostly about pipeline valuation appetite rather than launch execution.

✓Peer source comes from the stored AI memo or peer model

✓Grades and factor rows use RankAlpha API data when available

✓Missing peer scores remain blank instead of being estimated

✓Side-by-side comparison keeps the data contract visible

Top peerCYTKCytokinetics

KRYS

Krystal Biotech

CYTK

Cytokinetics

Grade

Momentum

Value

Sentiment

Setup Bias

Net —

Market Cap

Posture

Mixed

Defensive

Open Side-by-Side Comparison Compare all

Grade position vs CYTK

KRYS / CYTK

Grade Position

In line

KRYS vs. peer average (C vs. D)

60/100

Momentum

KRYS

Value

KRYS

Sentiment

KRYS

Rotation landscape

Peers ranked by the order returned from the peer source, with grades from the API.

Rank

Ticker

Company

Grade

Grade score

vs KRYS

20/100

40/100

Halozyme Therapeutics Inc Common

60/100

Even

BRKR

Bruker Corp Common

60/100

Even

CYTK is the first peer returned for this comparison set.